

**CLAIMS**

1. Association comprising 1) an antioxidant agent and 2) a mixed PPAR ligand for the  $\alpha$  and  $\gamma$  receptor sub-types, or a selective PPAR ligand for the  $\alpha$  receptor sub-type and a selective PPAR ligand for the  $\gamma$  receptor sub-type.
- 5     2. Association according to claim 1, wherein the PPAR ligand is a mixed ligand for the  $\alpha$  and  $\gamma$  receptor sub-types.
3. Association according to claim 1, comprising a selective ligand for the  $\alpha$  receptor sub-type and a selective ligand for the  $\gamma$  receptor sub-type.
- 10    4. Association according to claim 1, wherein the selective PPAR ligand for the  $\gamma$  receptor sub-type is rosiglitazone or an addition salt thereof with a pharmaceutically acceptable acid or base.
5. Association according to claim 1, wherein the antioxidant agent is ubiquinone or coenzyme Q<sub>10</sub>.
6. Association, which is rosiglitazone and coenzyme Q<sub>10</sub>.
- 15    7. Pharmaceutical compositions comprising as active ingredient one or more PPAR ligands in association with an antioxidant agent according to one of claims 1 to 6, on their own or in combination with one or more pharmaceutically acceptable excipients.
8. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.
- 20    9. Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of obesity caused by a therapeutic treatment.

**10.** Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of obesity caused by treatment for type I or II diabetes.

**11.** Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

**12.** Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

**13.** Pharmaceutical compositions according to claim 7 for use in the manufacture of a medicament for the treatment of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.

**14.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

**15.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.

**16.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

**17.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.

**18.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

5      **19.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.

**20.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

10      **21.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.

**22.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of  
15      overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

**23.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.

20      **24.** Use of an association comprising one or more PPAR ligands and an antioxidant agent in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.

**25.** Use of an association according to one of claims 1 to 6 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a

body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.